Introduction
Skeletal muscle makes up approximately 40% of the total body mass; it is essential in providing structural support, to regulate motion and as an energy store, thereby playing a major role in the overall metabolism. Skeletal muscle retains a high plasticity in order to respond to various stimuli, which subsequently lead to changes in gene transcription and translation. Aside from the obvious transcription factors, non‐coding RNAs have received much attention over the last decade and can be subclassed into long non‐coding RNA and small non‐coding RNA termed microRNA (miR). These miRs are similar to mRNA when first transcribed as primary RNA and are subsequently processed by the endoribonuclease DROSHA associated with PASHA to a precursor miR, which is further processed by the endoribonuclease DICER1 to form mature miRs.1 The mature miR binds to its target mRNAs leading to a blocked translation or degradation thereby providing the cell with a post‐transcriptional control of gene expression.2, 3
While some miRs are expressed ubiquitously in most tissues and cell types, other miRs are highly and specifically enriched in certain tissues.4 MyomiRs comprise a group of miRs, who display an enriched expression in skeletal muscle including miR‐1, miR‐133a, miR‐133b, miR‐206, miR‐208, miR‐208b, miR‐486, and miR‐499. These miRs are under the transcriptional control of myogenic regulatory factors such as MyoD, myogenin, Myf5, and MRF4.5 The expression of MyomiRs is modulated in skeletal muscle growth, its development and maintenance, and during atrophy.5 Two key players of muscle wasting are the E3 ubiquitin ligases MAFbx and MuRF‐1, the latter being the only E3 ubiquitin ligase known to target contractile proteins in catabolic conditions6 and which can be inhibited by small molecules.7 The related proteins MuRF‐2 and MuRF‐3 bind to microtubules and are implicated in sarcomere formation with evident functional redundancy, which has proven to be important for the maintenance of skeletal muscle, as double knockout mice lead to myopathy, reduced fore generation, and fibre type shift.8 In contrast to healthy adaptation, not only myomiRs are regulated in cancer cachexia, a recent publication showed an up‐regulation of hsa‐miR‐3184‐3p, hsa‐miR‐423‐5p, hsa‐let‐7d‐3p, hsa‐miR‐1296‐5p, hsa‐miR‐345‐5p, hsa‐miR‐532‐5p, hsa‐miR‐423‐3p, and hsa‐miR‐199a‐3p, but no down‐regulation of miRs in skeletal muscle biopsies of patients with pancreatic and colorectal cancer (Table 1).9 In a rat model of paralysed muscle by spinal cord injury, a down‐regulation of miRs 23a, 23b, 27b, 145, and 206 was observed 56 days after injury,10 while injection of 30 μg of mir‐206 attenuated muscle loss in a rat denervation model.11 In patients with chronic obstructive pulmonary disease (COPD), an up‐regulation of miR‐542‐3p/5p in quadricep muscle has been described, which caused muscle wasting and reduced mitochondrial function when overexpressed in mice possibly due to a suppression of the mitochondrial ribosomal protein MRPS10, reduced 12S ribosomal RNA expression, and increased TGF‐b signalling.12 In patients with COPD with a low fat free mass, an increased expression of miR‐675 in quadricep muscle was shown to repress muscle regeneration in vitro.13 Moreover, quadricep expression of miR‐422a was positively associated with muscle strength (maximal voluntary contraction r = 0.59, P < 0.001 and r = 0.51, P = 0.004, for COPD and aortic surgery, respectively) and inversely associated with the amount of muscle that would be lost in the first post‐operative week (r = −0.57, P < 0.001).14 Overexpression of miR‐23a/27a in muscle attenuated diabetes‐induced muscle cachexia and attenuates renal fibrosis lesions via muscle‐kidney crosstalk in streptozotocin‐induced diabetic mice.15 Recently, the lncRNA MAR1 has been shown to act as a miR‐487b scavenger to regulate Wnt5a protein expression leading to stimulated muscle differentiation and regeneration as well as increased strength in mice16 making the already complex miR regulatory system even more complicated.
Table 1.
miR up‐regulated | miR down‐regulated | Exercise type | Exercise duration | Reference |
---|---|---|---|---|
miR‐1, miR‐133a, miR‐133b, miR181a | miR‐9, miR‐23a, miR‐23b, miR‐31 | Acute exercise | Acute bout of moderate‐intensity endurance cycling | Russel et al.25 |
miR‐1, miR‐133a | Acute resistance exercise | 45 min of one‐legged knee extensor exercise | Ringholm et al.26 | |
miR‐1 | 12 weeks of training with two weekly resistance exercise sessions | 12 weeks of training with two weekly resistance exercise sessions | Mueller et al.27 | |
miR‐1, miR‐133a, miR‐133b, miR‐206 | Endurance | Cycle ergometer five times per week frequency for 12 weeks | Nielsen et al.28 | |
miR‐1, miR‐29b | Endurance | 10 days of endurance training | Russel et al.25 | |
miR‐136, miR‐200c, miR‐376, miR‐377, miR‐499b, miR‐558 | miR‐28, miR‐30d, miR‐204, miR‐330, miR‐345, miR‐375, miR‐449c, miR‐483, miR‐509, miR‐520a, miR‐548, miR‐628, miR‐653, miR‐670, miR‐889, miR‐1245a, miR‐1270, miR‐1280, miR‐1322, miR‐3180 | Chronic resistance exercise | 12‐week lower body resistance exercise | Ogasawara et al.29 |
miR‐451 | miR‐26a, miR‐29a, miR‐378 | Resistance exercise | 12‐week resistance exercise training program (pushing, pulling, and leg exercises, with 60 weight‐lifting sessions in total | Davidsen et al.30 |
miR‐133a, miR‐378, miR‐486 | Resistance exercise | 8 × 5 unilateral leg press repetitions on each leg at 80% of the 1repitition maximum | Fyfe et al.31 |
miRs can be actively secreted from a cell or leaking through the membrane in response to various stimuli and insults resulting in varying circulating miR levels in the blood, which are relatively stable making miRs interesting for the use as biomarkers and therapeutic targets.1 This is of particular importance in muscle wasting, as there are very few blood‐based biomarkers such as myostatin or agrinin that correlated with muscle mass.17, 18, 19, 20, 21 Several other circulating factors like GDF‐15,22 activin A,23 and low testosterone24 have been associated with muscle loss and survival in sarcopenia and cachexia and therefore can be considered potential biomarkers, but need to be validated in large trials. miRs could serve not only as biomarkers for muscle status and wasting but also as biomarkers to monitor muscle regeneration and therapy effects.
Resistance exercise has been of particular interest in sarcopenia and also in cachexia.32, 33, 34, 35, 36, 37 Moreover, exercise mimetics such as trimetazidine are of interest in the therapy of muscle atrophy,38 but also need companion biomarkers. MyomiRs are strongly regulated in resistance exercise, and their expression patterns in muscle as well as their plasma pattern levels may have the potential to serve as biomarkers for exercise, and regular monitoring in sarcopenic or cachectic patients could prevent detrimental over‐exercise.
Conflict of interest
None declared.
Acknowledgements
The authors certify that they comply with the ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017.39
Suzuki, T. , and Springer, J. (2018) MicroRNAs in muscle wasting. Journal of Cachexia, Sarcopenia and Muscle, 9: 1209–1212. 10.1002/jcsm.12384.
References
- 1. Siracusa J, Koulmann N, Banzet S. Circulating myomiRs: a new class of biomarkers to monitor skeletal muscle in physiology and medicine. J Cachexia Sarcopenia Muscle 2018;9:20–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014;15:509–524. [DOI] [PubMed] [Google Scholar]
- 3. Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol 2018;1. [DOI] [PubMed] [Google Scholar]
- 4. Sood P, Krek A, Zavolan M, Macino G, Rajewsky N. Cell‐type‐specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A 2006;103:2746–2751. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Sharma M, Juvvuna PK, Kukreti H, McFarlane C. Mega roles of microRNAs in regulation of skeletal muscle health and disease. Front Physiol 2014;5:239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Polge C, Cabantous S, Deval C, Claustre A, Hauvette A, Bouchenot C, et al. A muscle‐specific MuRF1‐E2 network requires stabilization of MuRF1‐E2 complexes by telethonin, a newly identified substrate. J Cachexia Sarcopenia Muscle 2018;9:129–145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Bowen TS, Adams V, Werner S, Fischer T, Vinke P, Brogger MN, et al. Small‐molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. J Cachexia Sarcopenia Muscle 2017;8:939–953. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Lodka D, Pahuja A, Geers‐Knorr C, Scheibe RJ, Nowak M, Hamati J, et al. Muscle RING‐finger 2 and 3 maintain striated‐muscle structure and function. J Cachexia Sarcopenia Muscle 2016;7:165–180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Narasimhan A, Ghosh S, Stretch C, Greiner R, Bathe OF, Baracos V, et al. Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. J Cachexia Sarcopenia Muscle 2017;8:405–416. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. De Gasperi R, Graham ZA, Harlow LM, Bauman WA, Qin W, Cardozo CP. The signature of microRNA dysregulation in muscle paralyzed by spinal cord injury includes downregulation of microRNAs that target myostatin signaling. PLoS One 2016;11:e0166189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Huang QK, Qiao HY, Fu MH, Li G, Li WB, Chen Z, et al. miR‐206 attenuates denervation‐induced skeletal muscle atrophy in rats through regulation of satellite cell differentiation via TGF‐beta1, Smad3, and HDAC4 signaling. Med Sci Monit 2016;22:1161–1170. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Garros RF, Paul R, Connolly M, Lewis A, Garfield BE, Natanek SA, et al. MicroRNA‐542 promotes mitochondrial dysfunction and SMAD activity and is elevated in intensive care unit‐acquired weakness. Am J Respir Crit Care Med 2017;196:1422–1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Lewis A, Lee JY, Donaldson AV, Natanek SA, Vaidyanathan S, Man WD, et al. Increased expression of H19/miR‐675 is associated with a low fat‐free mass index in patients with COPD. J Cachexia Sarcopenia Muscle 2016;7:330–344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Paul R, Lee J, Donaldson AV, Connolly M, Sharif M, Natanek SA, et al. miR‐422a suppresses SMAD4 protein expression and promotes resistance to muscle loss. J Cachexia Sarcopenia Muscle 2018;9:119–128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Zhang A, Li M, Wang B, Klein JD, Price SR, Wang XH. miRNA‐23a/27a attenuates muscle atrophy and renal fibrosis through muscle‐kidney crosstalk. J Cachexia Sarcopenia Muscle 2018;9:755–770. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Zhang ZK, Li J, Guan D, Liang C, Zhuo Z, Liu J, et al. A newly identified lncRNA MAR1 acts as a miR‐487b sponge to promote skeletal muscle differentiation and regeneration. J Cachexia Sarcopenia Muscle 2018;9:613–626. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Calvani R, Marini F, Cesari M, Tosato M, Anker SD, von Haehling S, et al. S. consortium, Biomarkers for physical frailty and sarcopenia: state of the science and future developments. J Cachexia Sarcopenia Muscle 2015;6:278–286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Loncar G, Springer J, Anker MS, Doehner W, Lainscak M. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle 2016;7:246–260. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Scherbakov N, Knops M, Ebner N, Valentova M, Sandek A, Grittner U, et al. Evaluation of C‐terminal agrin fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation. J Cachexia Sarcopenia Muscle 2016;7:60–67. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. von Haehling S. Casting the net broader to confirm our imaginations: the long road to treating wasting disorders. J Cachexia Sarcopenia Muscle 2017;8:870–880. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. J Cachexia Sarcopenia Muscle 2017;8:915–925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Patel MS, Lee J, Baz M, Wells CE, Bloch S, Lewis A, et al. Growth differentiation factor‐15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo. J Cachexia Sarcopenia Muscle 2016;7:436–448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Loumaye A, de Barsy M, Nachit M, Lause P, van Maanen A, Trefois P, et al. Circulating activin A predicts survival in cancer patients. J Cachexia Sarcopenia Muscle 2017;8:768–777. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Cheung AS, Gray H, Schache AG, Hoermann R, Lim Joon D, Zajac JD, et al. Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case‐control study. J Cachexia Sarcopenia Muscle 2017;8:102–112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Russell AP, Lamon S, Boon H, Wada S, Guller I, Brown EL, et al. Regulation of miRNAs in human skeletal muscle following acute endurance exercise and short‐term endurance training. J Physiol 2013;591:4637–4653. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Ringholm S, Bienso RS, Kiilerich K, Guadalupe‐Grau A, Aachmann‐Andersen NJ, Saltin B, et al. Bed rest reduces metabolic protein content and abolishes exercise‐induced mRNA responses in human skeletal muscle. Am J Physiol Endocrinol Metab 2011;301:E649–E658. [DOI] [PubMed] [Google Scholar]
- 27. Mueller M, Breil FA, Lurman G, Klossner S, Fluck M, Billeter R, et al. Different molecular and structural adaptations with eccentric and conventional strength training in elderly men and women. Gerontology 2011;57:528–538. [DOI] [PubMed] [Google Scholar]
- 28. Nielsen S, Scheele C, Yfanti C, Akerstrom T, Nielsen AR, Pedersen BK, et al. Muscle specific microRNAs are regulated by endurance exercise in human skeletal muscle. J Physiol 2010;588:4029–4037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Ogasawara R, Akimoto T, Umeno T, Sawada S, Hamaoka T, Fujita S. MicroRNA expression profiling in skeletal muscle reveals different regulatory patterns in high and low responders to resistance training. Physiol Genomics 2016;48:320–324. [DOI] [PubMed] [Google Scholar]
- 30. Davidsen PK, Gallagher IJ, Hartman JW, Tarnopolsky MA, Dela F, Helge JW, et al. High responders to resistance exercise training demonstrate differential regulation of skeletal muscle microRNA expression. J Appl Physiol (1985) 2011;110:309–317. [DOI] [PubMed] [Google Scholar]
- 31. Fyfe JJ, Bishop DJ, Zacharewicz E, Russell AP, Stepto NK. Concurrent exercise incorporating high‐intensity interval or continuous training modulates mTORC1 signaling and microRNA expression in human skeletal muscle. Am J Physiol Regul Integr Comp Physiol 2016;310:R1297–R1311. [DOI] [PubMed] [Google Scholar]
- 32. Springer J, Springer JI, Anker SD. Muscle wasting and sarcopenia in heart failure and beyond: update 2017. ESC Heart Fail 2017;4:492–498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Barbat‐Artigas S, Garnier S, Joffroy S, Riesco E, Sanguignol F, Vellas B, et al. Caloric restriction and aerobic exercise in sarcopenic and non‐sarcopenic obese women: an observational and retrospective study. J Cachexia Sarcopenia Muscle 2016;7:284–289. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Pinto CL, Botelho PB, Carneiro JA, Mota JF. Impact of creatine supplementation in combination with resistance training on lean mass in the elderly. J Cachexia Sarcopenia Muscle 2016;7:413–421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Snijders T, Nederveen JP, Joanisse S, Leenders M, Verdijk LB, van Loon LJ, et al. Muscle fibre capillarization is a critical factor in muscle fibre hypertrophy during resistance exercise training in older men. J Cachexia Sarcopenia Muscle 2017;8:267–276. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Solheim TS, Laird BJA, Balstad TR, Stene GB, Bye A, Johns N, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle 2017;8:778–788. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Song M, Chen FF, Li YH, Zhang L, Wang F, Qin RR, et al. Trimetazidine restores the positive adaptation to exercise training by mitigating statin‐induced skeletal muscle injury. J Cachexia Sarcopenia Muscle 2018;9:106–118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Molinari F, Pin F, Gorini S, Chiandotto S, Pontecorvo L, Penna F, et al. The mitochondrial metabolic reprogramming agent trimetazidine as an ‘exercise mimetic’ in cachectic C26‐bearing mice. J Cachexia Sarcopenia Muscle 2017;8:954–973. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017. J Cachexia Sarcopenia Muscle 2017;8:1081–1083. [DOI] [PMC free article] [PubMed] [Google Scholar]